Synthesis of some novel hydrazide-hydrazones derived from etodolac as potential anti-prostate cancer agents

Year 2022, Volume: 26 Issue: 1, 1 - 12, 28.06.2025

Hande Cevher Koç İrem Atlıhan , Pınar Mega Tiber Oya Orun , Ş.güniz Küçükgüzel

Abstract

(R,S)-Etodolac [1,8-diethyl-1,3,4,9-tetrahydrapyrano(3,4-b)indole-1-acetic acid] is a nonsteroidal antiinflammatory drug that contains carboxylic acid group with the structure of pyrano[3,4-b]indole. In this study, a series of novel (R,S)-Etodolac derivatives (3a-l) bearing hydrazide-hydrazone moiety were synthesized. The structures of these compounds were characterized by spectral (1H-NMR and FT-IR analyses) methods. All synthesized compounds were screened for anticancer activity against androgen-independent prostate adenocarcinoma (PC-3, DU-145) and androgen-dependent prostate adenocarcinoma (LNCaP) cell lines by using WST-8 colorimetric method. This method was used for cell viability and cytotoxicity analysis. Compound 3b (SGK-720) [2-(1,8-diethyl-1,3,4,9tetrahydropyrano[3,4-b]indole-1-yl)acetic acid[(2,6-dichlorophenyl)methylene]hydrazides] showed 10.36, 5.24, 15.53 µM anticancer activity against PC3, DU145, LNCaP cancer cell lines, respectively. According to JC-1 mitochondrial membrane potential test and Annexin V/PI staining, 3b was found to have apoptotic effect on these cancer cells. It is concluded that compound 3b containing 2,6-dichloro substituents may be one of the candidate molecules to cope with prostate cancer.

Keywords

Etodolac , hydrazide-hydrazone , anticancer activity , apoptosis , WST-8 colorimetric method

References

• [1] Kamijo T, Sato T, Nagatomi Y, Kitamura T. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001; 8(7): 35-39. [CrossRef]
• [2] Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-2 inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology. 2005; 66(6): 12391244. [CrossRef]
• [3] Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M, Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of e-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology. 2008; 71(1): 156-160. [CrossRef]
• [4] Çıkla P, Özsavcı D, Bingöl-Özakpınar Ö, Şener A, Çevik Ö, Özbaş-Turan S, Akbuğa J, Şahin F, Küçükgüzel ŞG. Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. Arch Pharm (Weinheim). 2013; 346(5): 367-379. [CrossRef]
• [5] Çıkla-Süzgün P, Kaushik-Basu N, Basu A, Arora P, Talele TT, Durmaz I, Cetin-Atalay R, Kucukguzel SG. Anti-cancer and anti-hepatitis C virus NS5B polymerase activity of etodolac 1,2,4-triazoles. J Enzyme Inhib Med Chem. 2015; 30(5): 778-785. [CrossRef]
• [6] Çoruh I, Çevik Ö, Yelekçi K, Djikic T, Küçükgüzel ŞG. Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitors. Arch Pharm (Weinheim). 2018; 351(3-4): e1700195. [CrossRef]
• [7] Rollas S, Küçükgüzel ŞG. Biological activities of hydrazone derivatives. Molecules. 2007; 12: 1910-1939. [CrossRef]
• [8] Kömürcü ŞG, Rollas S, Ülgen M, Gorrod JW, Çevikbaş A. Evaluation of some arylhydrazones of p-aminobenzoic acid hydrazide as antimicrobial agents and their in-vitro hepatic microsomal metabolism. Boll Chim Farm. 1995; 134(7): 375-379.
• [9] Koçyiğit-Kaymakçıoğlu B, Ünsalan S, Küçükgüzel ŞG, Şener G, Rollas S. HPLC analysis of in vivo metabolites of 4nitrobenzoic acid [(5-nitro-2-thiophenyl)methylene]hydrazide in rats. Eur J Drug Metab Pharmacokinet. 2007; 32(4): 197-203. [CrossRef]
• [10] Rollas S, Küçükgüzel ŞG. Hydrazone, amide, carbamate, macromolecular and other prodrugs of doxorubicin. Open Drug Deliv J. 2008; 2: 77-85. [CrossRef]
• [11] Aydın S, Kaushik-Basu N, Arora P, Basu A, Nichols DB, Talele TT, Akkurt M, Çelik İ, Büyükgüngör O, Küçükgüzel ŞG. Microwave assisted synthesis of some novel flurbiprofen hydrazide-hydrazones as anti-HCV NS5B and anticancer agents. Marmara Pharm J. 2013; 17: 181-189. [CrossRef]
• [12] Küçükgüzel ŞG, Koç D, Çıkla-Süzgün P, Özsavcı D, Bingöl-Özakpınar Ö, Mega-Tiber P, Orun O, Erzincan P, SağErdem S, Şahin F. Synthesis of tolmetin hydrazide-hydrazones and discovery of a potent apoptosis inducer in colon cancer cells. Arch Pharm (Weinheim). 2015; 348(10): 730-742. [CrossRef]
• [13] Şenkardeş S, Kaushik-Basu N, Durmaz İ, Manvar D, Basu A, Atalay R, Küçükgüzel ŞG. Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agent and hepatocellular carcinoma inhibitors. Eur J Med Chem. 2016; 108: 301-308. [CrossRef]
• [14] Çıkla-Süzgün P, Küçükgüzel ŞG. Recent advances in apoptosis: the role of hydrazones. Mini Rev Med Chem. 2019; 19(17): 1427-1442. [CrossRef]
• [15] Han Mİ, Bekçi H, Uba Aİ, Yıldırım Y, Karasulu E, Cumaoğlu A, Karasulu HY, Yelekçi K, Yılmaz Ö, Küçükgüzel ŞG.Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazidehydrazones derived from (S)-naproxen. Arch Pharm (Weinheim). 2019; 352(6): e1800365. [CrossRef]
• [16] Han Mİ, Atalay P, İmamoğlu N, Küçükgüzel ŞG. Synthesis, characterization and anticancer activity of novel hydrazide-hydrazones derived from ethyl paraben. J Res Pharm. 2020; 24(3): 341-349. [CrossRef]
• [17] Şenkardeş S, Türe A, Ekrek S, Durak AT, Abbak M, Çevik Ö, Kaşkatepe B, Küçükgüzel İ, Küçükgüzel ŞG. Novel 2,6disubstituted pyridine hydrazones: synthesis, anticancer activity, docking studies and effects on caspase-3-mediated apoptosis. J Mol Struct. 2021; 1223: 128962. [CrossRef]
• [18] Han Mİ, Atalay P, Tunç CÜ, Ünal G, Dayan S, Aydın Ö, Küçükgüzel ŞG. Design and synthesis of novel (S)-naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models. Bioorg Med Chem. 2021; 37: 116097. [CrossRef]
• [19] Rutavichyus A, Valiulene S, Kuodis Z. Isomerism of hydrazones of (2-benzothiazolylthio)- and (2benzoxazolylthio)acetic acids. Chem Heterocycl Comp. 1995; 31(5): 629-633. [CrossRef]
• [20] Rutavichyus A, Valiulene S, Kuodis Z. Synthesis and structure of hydrazones obtained from hydrazides of [5-(4pyridyl)-1,3,4-oxadiazol-2-ylthio]acetic or 2-[5-(4-pyridyl)-1,3,4-oxadiazol-2-ylthio]propionic acids. Chem Heterocycl Comp. 2000; 36(7): 851-856. [CrossRef]
• [21] Çıkla P, Tatar E, Küçükgüzel İ, Şahin F, Yurdakul D, Basu A, Krishnan R, Nichols DB, Kaushik-Basu N, Küçükgüzel ŞG. Synthesis and characterization of flurbiprofen hydrazide derivatives as potential anti-HCV, anticancer and antimicrobial agents. Med Chem Res. 2013; 22: 5685-5699. [CrossRef]
• [22] Vincenzo G, Franco P. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation. US 5,599,946. 1997.
• [23] Raghavan BV, Ramana KV, Khera B, Kumar N. Process for the preparation of 1,8-disubstituted-1,3,4,9tetrahydropyrano (3,4-b)-indole-1-acetic acid esters. US 6,331,638 B1. 2001.